✨
AI Summary
- VCs analyze why biotech development is slow and expensive compared to China.
- They identify 'three horsemen' strangling drug development costs and timelines.
- The episode explores how China's investigator-initiated trials are changing the competitive landscape.
Guests on This Episode
EH
Elliot Hershberg
1 podcast appearance
LN
Lada Nuzhna
1 podcast appearance